阿帕替尼联合复方苦参注射液治疗恶性肿瘤的临床研究

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Apatinib combined with Compound Kushen Injection in the treatment of malignant tumors.Methods A total of 40 patients with malignant tumors treated in our hospital from March to November in 2017 were selected as subjects.By the random number table method,all patients were evenly divided into two groups,20 cases in each group.In the control group,Apatinib alone was used,while in the research group,Apatinib combined with Compound Kushen Injection were adopted.The clinical effect,adverse reactions and hospitalization expenses and length of stay were observed and compared between the two groups.ResultsThe total effectiveness rate was 90.00%in the research group,which was higher than that in the control group(55.00%),the difference was statistically significant(P＜0.05).The incidence of adverse reactions was 10.00%in the research group,which was lower than that in the control group(40.00%),the difference was statistically significant(P＜0.05).The hospital stay in the research group was(104.19±22.17)d,which was shorter than that of the control group([155.37±32.73]d),the hospitalization expenses in the research group was(20 439.35±10 123.13)yuan,which was less than that of the control group([30 489.17±10 533.71]yuan),the differences were statistically significant(P＜0.05).Conclusion In the treatment of malignant tumors,combination of Apatinib and Compound Kushen Injection can decrease hospitalization expenses,shorten hospital stay,reduce adverse reactions,and achieve a good clinical effect in practicality.

Key words： Apatinib Compound Kushen Injection Malignant tumor

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHONG Hui
	ZHONG Zhen-wu
	WU Li-fang
	ZHONG Yu
	LIN Zhou-mei

Cite this article:

ZHONG Hui,ZHONG Zhen-wu,WU Li-fang, et al. Clinical study of Apatinib combined with Compound Kushen Injection in the treatment of malignant tumors[J]. 中国当代医药, 2018, 25(11): 130-132.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I11/130

[1]	高金平，韩涛，朴瑛，等.阿帕替尼联合替吉奥治疗老年或瘦弱患者晚期胃癌临床研究[J].临床军医杂志，2017，45（1）：9-12.
[2]	朱华云，孙小峰，周青，等.阿帕替尼联合化疗治疗晚期胃癌的临床研究[J].中国肿瘤外科杂志，2016，8（6）：394-396.
[3]	涂艳，彭枫.阿帕替尼治疗恶性肿瘤的临床研究进展[J].中国肿瘤临床，2016，43（12）：545-548.
[4]	朱丹，赵宏伟，赵健琦，等.肿瘤分子靶向药物阿帕替尼的临床研究进展[J].中国医院药学杂志，2017，37（2）：194-198.
[5]	杨宝玉，林小燕，王新利.阿帕替尼联合替吉奥治疗晚期胃癌效果观察[J].肿瘤研究与临床，2017，29（9）：92-95.
[6]	李威，满文玲，郭欢庆，等.TACE联合甲磺酸阿帕替尼治疗中晚期肝癌的临床研究[J].肿瘤药学，2017，7（1）：74-78.
[7]	杨泽冉，苏天昊，尉建安，等.肝动脉化疗栓塞术联合阿帕替尼治疗中晚期原发性肝癌疗效评价[J].中国肿瘤临床，2017，44（17）：880-885.
[8]	廖景升，刘琦，黎焕君，等.甲磺酸阿帕替尼治疗晚期原发性肝癌疗效及安全性观察[J].海南医学，2017，28（5）：714-716.
[9]	郎丰平，赵毓毅，范鹏.甲磺酸阿帕替尼治疗晚期胃癌的疗效及安全性分析[J].实用癌症杂志，2017，32（6）：996-998.
[10]	宋朝阳.肿节风注射液联合阿帕替尼治疗晚期胃癌的临床研究[J].现代药物与临床，2017，32（6）：1114-1117.
[11]	李旭，张翠翠，谭红叶，等.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果观察[J].中国生化药物杂志，2016，7（2）：91-93.
[12]	胡姗姗，向梅，卢萍，等.阿帕替尼联合替吉奥治疗老年一线晚期胃癌患者的临床效果分析[J].养生保健指南，2016，11（36）：33.
[13]	宋锦添，陈奕贵，许春伟，等.阿帕替尼治疗53例晚期原发性肝癌的疗效[J].临床与病理杂志，2017，37（3）：557-563.
[14]	吕丽婷，茅国新.阿帕替尼治疗晚期胃癌的近期效果及不良反应[J].交通医学，2017，31（1）：53-55.
[15]	彭秋霞，范娟，韩云炜.阿帕替尼治疗恶性肿瘤的研究进展[J].西南军医，2017，19（2）：176-179.
[16]	孙培培，张龙，张泰，等.单药阿帕替尼治疗二线及二线以上化疗失败的晚期大肠癌患者疗效分析[J].临床肿瘤学杂志，2017，22（7）：646-649.